SCHEMBL6440940

SCHEMBL6440940

CCCOc1nc(N)c(C#N)c(-c2ccncc2)c1C#N

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 9/20 0.62
ALDH1A1 P00352 9/20 0.62
MAPK1 P28482 3/20 0.62
KDM4E B2RXH2 11/20 0.56
HPGD P15428 5/20 0.52
NPSR1 Q6W5P4 5/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
MAPT P10636 4/20 0.52
RXFP1 Q9HBX9 3/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
ADORA1 P30542 6/20 0.50
HTT P42858 1/20 0.47
GLA P06280 1/20 0.45
USP2 O75604 2/20 0.44
TP53 P04637 1/20 0.44
ALOX15 P16050 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3550981 0.78 ADORA1 (0.60) HSD17B10ALDH1A1MAPK1KDM4EHPGD
SCHEMBL28379366 0.77 KDM4E (0.58) HSD17B10ALDH1A1MAPK1KDM4EHPGD
SCHEMBL7016201 0.76 ADORA1 (0.68) HSD17B10ALDH1A1MAPK1KDM4EHPGD
SCHEMBL27220350 0.75 KDM4E (0.60) HSD17B10ALDH1A1MAPK1KDM4EHPGD
SCHEMBL6462280 0.75 ADORA1 (0.63) HSD17B10ALDH1A1MAPK1KDM4EHPGD
SCHEMBL27220349 0.75 KDM4E (0.56) HSD17B10ALDH1A1MAPK1KDM4EHPGD
SCHEMBL6442682 0.75 HSD17B10 (0.62) HSD17B10ALDH1A1MAPK1KDM4EHPGD
SCHEMBL1421425 0.74 ADORA1 (0.56) HSD17B10ALDH1A1KDM4EHPGDNPSR1
SCHEMBL7014126 0.73 ADORA1 (0.65) HSD17B10ALDH1A1MAPK1ADORA1
SCHEMBL7018629 0.72 ADORA1 (0.54) HSD17B10ALDH1A1MAPK1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 HSD17B10 3742/4885ALDH1A1 534/4885MAPK1 4100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.